Why do so many individuals persist in taking psychoactive substances, including psychiatric drugs, after adverse mental and behavioral effects have become severe and even disabling? The author has previously proposed the brain-disabling principle of psychiatric treatment that all somatic psychiatric treatments impair the function of the brain and mind. Intoxication anosognosia (medication spellbinding) is an expression of this drug-induced mental disability. Intoxication anosognosia causes the victim to underestimate the degree of drug-induced mental impairment, to deny the harmful role that the drug plays in the person’s altered state, and in many cases compel the individual to mistakenly believe that he or she is functioning better. In the extreme, the individual displays out-of-character compulsively destructive behaviors, including violence toward self and others.
Your search for all content returned 16 results
This article describes 22 principles for the conduct of therapy or counseling, most of which are also applicable to all human relationships. The creation of a safe space and a caring, trustworthy relationship is essential to therapy and basic to the helping process. Conducting therapy requires the application of the highest ethics and ideals.
Electroconvulsive therapy (ECT) and the machines that deliver it have never been tested for safety and efficacy in order to receive approval from the Food and Drug Administration (FDA). The American Psychiatric Association and ECT advocates protested when the FDA took steps to classify the machines as posing “an unreasonable risk of illness or injury,” which would have required their testing before approval. Without requiring this testing, the FDA is now preparing to classify the treatment and the machines as safe. This article reviews evidence demonstrating that ECT is very harmful to the brain and mind and concludes that the FDA should demand the usual testing required before psychiatric treatments and machines are approved for marketing and use.
The newer antidepressants frequently cause suicide, violence, and manic-like symptoms of activation or overstimulation, presenting serious hazards to active-duty soldiers who carry weapons under stressful conditions. These antidepressant-induced symptoms of activation can mimic posttraumatic stress disorder and are likely to worsen this common disorder in soldiers, increasing the hazard when they are prescribed to military personnel. Antidepressants should not be prescribed to soldiers during or after deployment.
Psychiatric medications are not only dangerous to take on a regular basis, but they also become especially dangerous during changes in dosage, including dose reduction and withdrawal. This book provides the latest up-to-date clinical and research information regarding when and how to reduce or to withdraw from psychiatric medication. The book is divided into two parts. While Part I deals with the reasons to consider drug withdrawal or dose reduction. Part II discusses the withdrawal process. Although this book focuses on medication reduction and withdrawal, the person-centered collaborative approach is also a model for helping children, dependent adults, adults who are emotionally or cognitively impaired, and the elderly, as well as those going through psychiatric medication withdrawal. The book begins with reviews of adverse drug effects that may require drug reduction or withdrawal. It then discusses withdrawal effects for specific drugs to familiarize clinicians, patients, and families with these problems. Reasons for withdrawal for antipsychotic (neuroleptic) drugs, antidepressant drugs, stimulant drugs, sedatives and opiates, and lithium and mood stabilizers are described. Medication spellbinding (intoxication anosognosia) is caused by all psychoactive substances, and can lead to dangerous behaviors that are highly uncharacteristic of the individual. Prescribers and therapists who embrace a person-centered collaborative approach to therapy and to medication withdrawal will find it professionally gratifying and will help many patients and their families.
- Go to article: Exposure to SSRI Antidepressants In Utero Causes Birth Defects, Neonatal Withdrawal Symptoms, and Brain Damage
Exposure to SSRI Antidepressants In Utero Causes Birth Defects, Neonatal Withdrawal Symptoms, and Brain Damage
Pregnant mothers should avoid taking SSRI antidepressants—they are hazardous to the developing fetus, cause withdrawal symptoms in the newborn baby, and induce biochemical and morphological abnormalities in the brain. If pregnant mothers need help with sad or anxious feelings, they should seek counseling or psychotherapy, especially family therapy involving the child’s father, as well as other sources of emotional support.